Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis.Pediatric Pulmonology.  53:E21-E23. 2018
2016 Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.Current Medical Research and Opinion.  32:1789-1795. 2016
2015 Quantitative sinonasal symptom assessment in an unselected pediatric population with cystic fibrosis.American Journal of Rhinology.  29:357-361. 2015
2010 IL-10 delivery by AAV5 vector attenuates inflammation in mice with Pseudomonas pneumonia.Gene Therapy.  17:567-576. 2010
2009 Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis.American Journal of Respiratory Cell and Molecular Biology.  41:367-375. 2009
2009 Cost-effective airway cultures in the cystic fibrosis patient.American Journal of Otolaryngology.  30:150-152. 2009
2008 Oral instillation with surfactant phospholipid: a reliable alternative to intratracheal injection in mouse studies.Laboratory Animals.  42:294-304. 2008
2005 Enhancing rAAV vector expression in the lung.Journal of Gene Medicine.  7:842-850. 2005
2005 Emergency preparedness for the chronically ill.American Journal of Nursing.  105:68-72. 2005
2004 Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell Line.Molecular Therapy.  10:562-573. 2004
2002 Adeno-associated viral vectors for CF gene therapy.Methods in Molecular Medicine.  70:599-608. 2002
2000 Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients.Gene Therapy.  7:1783-1789. 2000
1997 Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls.Clinical immunology and immunopathology.  85:73-82. 1997
1993 Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteersInternational Journal of Clinical and Laboratory Research.  23:95-101. 1993
1991 Immunosuppressive effects of fish oil in normal human volunteers: Correlation with the in vitro effects of eicosapentanoic acid on human lymphocytesClinical immunology and immunopathology.  61:161-176. 1991

Research Overview

  • Cystic Fibrosis, Asthma, Patient Safety, Lung inflammation
  • Principal Investigator On

    Investigator On

  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Rare CFTR Mutation Cell Collection Protocol (RARE)  awarded by SEATTLE CHILDREN'S HOSPITAL 2016 - 2021
  • Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL 2018 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2020
  • Characterizing CFTR Modulated Changes in Sweat Chloride & Clinical Outcomes  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2017 - 2020
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2018 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2020
  • UAB Cystic Fibrosis Translational Development Center  awarded by Cystic Fibrosis Foundation 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2018 - 2019
  • Airways Clinical Research Centers (ACRC) Network  awarded by American Lung Association 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Losartan as Anti-Inflammatory Therapy to Augment F508del CFTR Recovery  awarded by University of Miami 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Implementation of the Depression and Anxiety Guideline: Award for a Mental Health Coordinator  awarded by Cystic Fibrosis Foundation 2016 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • Airways Clinical Research Centers (ACRC)  awarded by American Lung Association 2017 - 2018
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2018
  • Development of Standardized Measures of Barriers to Treatment Adherence: Field Testing and Psychometric Validation  awarded by CHILDREN'S HOSPITAL (BOSTON) 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • Airways Clinical Research Center (ACRC)  awarded by American Lung Association 2016 - 2017
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation 2016 - 2017
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation 2015 - 2016
  • Education And Training

  • Doctor of Medicine, University of South Carolina System : Columbia
  • University of Florida, Internship 1996
  • University of Florida, Residency 1998
  • University of Florida, Postdoctoral Fellowship 2001
  • Full Name

  • Isabel Virella-Lowell
  • Blazerid

  • ilowell